Search Result

Results for "

ischemic injury

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Akt (1) AMPK (1) Amyloid-β (2) Angiotensin Receptor (1) Angiotensin-converting Enzyme (ACE) (4) Apoptosis (11) Aquaporin (1) ATP Synthase (1) Dynamin (1) HBV (1) HPV (1) iGluR (2) Integrin (5) Isotope-Labeled Compounds (1) Keap1-Nrf2 (1) Leukotriene Receptor (1) MMP (1) Na+/H+ Exchanger (NHE) (1) nAChR (1) NADPH Oxidase (2) PARP (1) PDK-1 (1) Phosphatase (1) Phospholipase (1) PKG (1) Renin (1) ROCK (1) Ser/Thr Protease (1) STAT (2) Toll-like Receptor (TLR) (1) TRP Channel (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (22) Infection (1) Inflammation/Immunology (5) Metabolic Disease (2) Neurological Disease (26)

By Targets:

Adenosine Receptor (1)

Akt (1)

AMPK (1)

Amyloid-β (2)

Angiotensin Receptor (1)

Angiotensin-converting Enzyme (ACE) (4)

Apoptosis (11)

Aquaporin (1)

ATP Synthase (1)

Dynamin (1)

HBV (1)

HPV (1)

iGluR (2)

Integrin (5)

Isotope-Labeled Compounds (1)

Keap1-Nrf2 (1)

Leukotriene Receptor (1)

MMP (1)

Na+/H+ Exchanger (NHE) (1)

nAChR (1)

NADPH Oxidase (2)

PARP (1)

PDK-1 (1)

Phosphatase (1)

Phospholipase (1)

PKG (1)

Renin (1)

ROCK (1)

Ser/Thr Protease (1)

STAT (2)

Toll-like Receptor (TLR) (1)

TRP Channel (1)

By Research Areas:

Cancer (3)

Cardiovascular Disease (22)

Infection (1)

Inflammation/Immunology (5)

Metabolic Disease (2)

Neurological Disease (26)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-143333

Nrf2 activator-3	Keap1-Nrf2	Neurological Disease Inflammation/Immunology
Nrf2 activator-3 is a potent Nrf2 activator. Nrf2 activator-3 is used for cerebral ischemic injury research .

HY-109097

Otaplimastat SP-8203	MMP iGluR	Neurological Disease
Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury .

HY-149967

GluN2B-NMDAR antagonist-1	iGluR	Neurological Disease Inflammation/Immunology
GluN2B-NMDAR antagonist-1 is an orally active GluN2B-NMDAR antagonist. GluN2B-NMDAR antagonist-1 has neuroprotective activity. GluN2B-NMDAR antagonist-1 can be used for research of ischemic injury .

HY-P1061

Colivelin Maximum Cited Publications 47 Publications Verification	STAT Amyloid-β	Neurological Disease
Colivelin is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3?in vitro . Colivelin exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease . Colivelin has the potential for the treatment of alzheimer's disease and ischemic brain injury

HY-P1061A

Colivelin TFA Maximum Cited Publications 47 Publications Verification	STAT Amyloid-β Apoptosis	Neurological Disease
Colivelin TFA is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3?in vitro . Colivelin TFA exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease . Colivelin TFA has the potential for the treatment of alzheimer's disease and ischemic brain injury .

HY-123203

CP-608039	Adenosine Receptor	Cardiovascular Disease
CP-608039 is a potent and selective adenosine A3 receptor agonist. CP-608039 can be used for ischemic myocardial injury research .

HY-116444

16(S)-HETE	Others	Neurological Disease
16(S)-HETE is an endogenous inhibitor of neutrophil activity and can be used in the study of acute ischemic brain injury .

HY-W704968

2-Oxo-zoniporide hydrochloride	Na+/H+ Exchanger (NHE)	Cardiovascular Disease
2-Oxo-zoniporide hydrochloride is an oral active sodium-hydrogen exchanger type 1 (NHE-1) inhibitor and can be used for study of myocardial ischemic injury .

HY-P5754

TAT-NEP1-40	Apoptosis	Neurological Disease
TAT-NEP1-40 is a BBB-penatrable peptide. TAT-NEP1-40 protects PC12 cells against oxygen and glucose deprivation (OGD), and promotes neurite outgrowth. TAT-NEP1-40 also improves ischemia-induced neurologic outcomes by inhibiting cell apoptosis in ischemic brains. TAT-NEP1-40 can be used for research of CNS injuries, such as axonal regeneration and functional recovery after stroke .

HY-P5754A

TAT-NEP1-40 TFA	Apoptosis	Neurological Disease
TAT-NEP1-40 TFA is a BBB-penatrable peptide. TAT-NEP1-40 TFA protects PC12 cells against oxygen and glucose deprivation (OGD), and promotes neurite outgrowth. TAT-NEP1-40 TFA also improves ischemia-induced neurologic outcomes by inhibiting cell apoptosis in ischemic brains. TAT-NEP1-40 TFA can be used for research of CNS injuries, such as axonal regeneration and functional recovery after stroke .

HY-P6437

Drp1 peptide inhibitor P110	Dynamin	Cardiovascular Disease Neurological Disease
Drp1 peptide inhibitor P110 (Compound P110) is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 can inhibit the activation of Drp1, prevent MPTP-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .

HY-P2060

CGP 44099	Renin	Cardiovascular Disease
CGP 44099 is a renin inhibitor. CGP 44099 can be used to study the ischemic injury and reperfusion arrhythmias in rat hearts .

HY-148226

20-5,14-HEDGE	Others	Cardiovascular Disease
20-5,14-HEDGE is a 20-HETE analog. 20-5,14-HEDGE protects against lung ischemic reperfusion injury in rats .

HY-112248A

HAMI 3379	Leukotriene Receptor	Cardiovascular Disease Inflammation/Immunology
HAMI 3379 is a potent and selective CysLT₂ receptor antagonist. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury, and attenuates microglia-related inflammation .

HY-N4098

Incensole Acetate	Apoptosis	Neurological Disease
Incensole acetate is a main constituent of Boswellia carterii resin, has neuroprotective effects against neuronal damage in traumatic and ischemic head injury. Incensole acetate reduces Aβ25–35-triggered apoptosis in hOBNSCs .

HY-106592A

U-74389G PNU74389G (meleate)	Others	Cardiovascular Disease Others
U-74389G (PNU74389G meleate) is an antioxidant, can inhibit lipid peroxidation reactions. U-74389G can protect against ischemia-reperfusion injury and be widely used in animal models of ischemic injury and hypertension. U-74389G shows anti-inflammatory activity .

HY-117627

L 158338	Angiotensin Receptor	Cardiovascular Disease
L 158338 is an angiotensin II receptor antagonist. L 158338 alleviates acidosis and increases coronary blood flow during the ischemic period and increases coronary blood flow during the reperfusion period. L 158338 can be used to study myocardial injury during ischemia and reperfusion .

HY-153977

GLX481304	NADPH Oxidase	Cardiovascular Disease
GLX481304 is a specific inhibitor of Nox-2 and -4, with IC₅₀s of 1.25 μM. GLX481304 suppresses ROS production in isolated mouse cardiomyocytes and improves cardiomyocyte contractility. GLX481304 can be used for research of ischemic injury to the heart .

HY-N3239

Mulberrofuran G	NADPH Oxidase HBV
Mulberrofuran G protects ischemic injury-induced cell death via inhibition of NOX4-mediated ROS generation and ER stress . Mulberrofuran G shows moderate inhibiting activity of hepatitis B virus (HBV) DNA replication with IC₅₀ of 3.99 μM .

HY-N4098R

Incensole Acetate (Standard)	Apoptosis	Neurological Disease
Incensole Acetate (Standard) is the analytical standard of Incensole Acetate. This product is intended for research and analytical applications. Incensole acetate is a main constituent of Boswellia carterii resin, has neuroprotective effects against neuronal damage in traumatic and ischemic head injury. Incensole acetate reduces Aβ25–35-triggered apoptosis in hOBNSCs .

HY-105692

DR2313	PARP	Neurological Disease
DR2313 is a potent, selective, competitive and brain-penetrant inhibitor of poly(ADP-ribose) polymerase (PARP), with IC₅₀s of 0.20 μM and 0.24 μM for PARP-1 and PARP-2, respectively. DR2313 exhibits neuroprotective effects on ischemic injuries in vitro and in vivo .

HY-160509

BTB 06061	TRP Channel	Neurological Disease
BTB 06061 is a TRPM7 inhibitor and can be used for study of ischemic disease .

HY-137629

Sp-8-pCPT-PET-cGMPS	PKG	Cardiovascular Disease
Sp-8-pCPT-PET-cGMPS is an activator for PKG-I. Sp-8-pCPT-PET-cGMPS can be used for research of NO/NOS/sGC/PKG-I signaling pathway in cardiac differentiation .

HY-17369

Tirofiban hydrochloride monohydrate 1 Publications Verification L700462 hydrochloride monohydrate; MK383 hydrochloride monohydrate	Integrin	Cardiovascular Disease
Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-17369B

Tirofiban 1 Publications Verification L700462; MK383	Integrin	Cardiovascular Disease
Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-17369A

Tirofiban hydrochloride L700462 hydrochloride; MK383 hydrochloride	Integrin	Cardiovascular Disease
Tirofiban (L700462) hydrochloride is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-W017540

Cyclocreatine 1 Publications Verification	ATP Synthase	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer .

HY-120327

KY-226 1 Publications Verification	Phosphatase	Neurological Disease Metabolic Disease
KY-226 is a potent, selective, orally active and allosteric protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC₅₀ of 0.25 μM, and without PPARγ agonist activity. KY-226 exerts anti-diabetic and anti-obesity effects by enhancing insulin and leptin signaling, respectively. KY-226 also protects neurons from cerebral ischemic injury .

HY-17369BR

Tirofiban (Standard)	Integrin	Cardiovascular Disease
Tirofiban (Standard) is the analytical standard of Tirofiban. This product is intended for research and analytical applications. Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-17369R

Tirofiban hydrochloride monohydrate (Standard)	Integrin	Cardiovascular Disease
Tirofiban (hydrochloride monohydrate) (Standard) is the analytical standard of Tirofiban (hydrochloride monohydrate). This product is intended for research and analytical applications. Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-139598

LFHP-1c	Phospholipase	Cardiovascular Disease
LFHP-1c is an PGAM5 inhibitor with neuroprotective activity in brain ischemic stroke. LFHP-1c protects blood-brain barrier integrity from ischemia-induced injury. LFHP-1c binds to endothelial PGAM5 to inhibit the activity of PGAM5 phosphatase and the interaction of PGAM5 with NRF2. LFHP-1c exhibits in vitro and in vivo protection .

HY-124379

TPCK 1 Publications Verification L-1-Tosylamido-2-phenylethyl chloromethyl ketone; L-TPCK	Ser/Thr Protease HPV Apoptosis PDK-1	Infection Neurological Disease Inflammation/Immunology Cancer
TPCK (L-1-Tosylamido-2-phenylethyl chloromethyl ketone; L-TPCK) is an effective serine protease inhibitor and also a blocker of the PDK1/Akt pathway. TPCK can modify the E7 protein in actively keratinocyte cells. TPCK can induce cellular apoptosis, suppress tumor growth, reduce hypoxic-ischemic brain injury in rat pups, and affect vascular permeability in inflamed rats .

HY-N8931

Monomethyl lithospermate Lithospermic acid monomethyl ester	Akt	Neurological Disease
Monomethyl lithospermate activates the PI3K/AKT pathway, which plays a protective role in nerve injury. Monomethyl lithospermate can improve the survival ability of SHSY-5Y cells, inhibit the breakdown of mitochondrial membrane potential (MMOP) and inhibit cell apoptosis. Monomethyl lithospermate also reduced the level of oxidative stress in the brain tissue of rats with middle artery occlusion (MCAO) and improved nerve damage in rats with ischemic stroke (IS) .

HY-162596

NRL-1049 BA-1049	ROCK	Neurological Disease
NRL-1049 (BA-1049) is a ROCK2 selective inhibitor (IC₅₀: 0.59 µM and 26 µM for ROCK2 and ROCK1 respectively). NRL-1049 reduces Lysophosphatidic acid induced ROCK activation in endothelial cells. NRL-1049 reduces lesion volume and hemorrhagic transformation in a mouse model of cavernous angiomas. NRL-1049 also preserves the BBB and suppresses seizures after brain injury, and inhibits hemorrhagic transformation after ischemic stroke in mice .

HY-115460

AER-271 1 Publications Verification	Aquaporin	Cardiovascular Disease Neurological Disease
AER-271, a phosphonate proagent derivative of AER-270, is an aquaporin-4 (AQP4) inhibitor for the research of acute ischemic stroke .

HY-100206

5α-Androstane-3β,5,6β-triol	AMPK	Neurological Disease
5α-Androstane-3β,5,6β-triol is a neuroprotectant. 5α-Androstane-3β,5,6β-triol can remarkably reverse intracellular acidification and alleviate neuronal injury through the inhibition of AMPK signaling. 5α-Androstane-3β,5,6β-triol remarkably reduced the infarct volume and attenuated neurologic impairment in acute ischemic stroke models of middle cerebral artery occlusion in vivo .

HY-W818693

3-Hydroxy-3-phenylpentanamide	Others	Cancer
3-Hydroxy-3-phenylpentanamide is a compound with neuroprotective activity. 3-Hydroxy-3-phenylpentanamide shows protective effects against ischemic brain injury and cerebral hemorrhage. 3-Hydroxy-3-phenylpentanamide is studied in psychiatry as a potential anxiety, depression and addiction suppressant compound. 3-Hydroxy-3-phenylpentanamide shows antitumor activity in oncology, acting by inducing apoptosis and inhibiting tumor growth. 3-Hydroxy-3-phenylpentanamide also has protective effects against epileptic seizures .

HY-126049

(S)-Oxiracetam (S)-(-)-Oxiracetam; (S)-ISF2522	Apoptosis	Neurological Disease
(S)-oxiracetam (S-ORC) is an inhibitor targeting apoptosis. S-ORC reduces brain infarct size and lessens neurological dysfunction in middle cerebral artery occlusion/reperfusion (MCAO/R) models. S-ORC prevents neuronal apoptosis via activating PI3K/Akt/GSK3β signaling pathway via α7 nAChR after ischemic stroke. S-ORC can prevent neuronal death after ischemic stroke .

HY-B0378A

Moexipril hydrochloride RS-10085	Angiotensin-converting Enzyme (ACE) Apoptosis	Cardiovascular Disease
Moexipril hydrochloride (RS-10085) is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride). Moexipril hydrochloride exhibits antihypertensive and neuroprotective effects ^- .

HY-117281

Moexipril	Angiotensin-converting Enzyme (ACE) Apoptosis	Cardiovascular Disease Neurological Disease
Moexipril is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride). Moexipril exhibits antihypertensive and neuroprotective effects ^- .

HY-117281S1

Moexipril-d3	Apoptosis Angiotensin-converting Enzyme (ACE) Isotope-Labeled Compounds	Cardiovascular Disease Neurological Disease
Moexipril-d₃ is deuterated labeled Moexipril (HY-117281). Moexipril is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila hydrochloride. Moexipril exhibits antihypertensive and neuroprotective effects ^- .

HY-B0378AR

Moexipril hydrochloride (Standard)	Angiotensin-converting Enzyme (ACE) Apoptosis	Cardiovascular Disease
Moexipril (hydrochloride) (Standard) is the analytical standard of Moexipril (hydrochloride). This product is intended for research and analytical applications. Moexipril hydrochloride (RS-10085) is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride). Moexipril hydrochloride exhibits antihypertensive and neuroprotective effects - .

HY-P5117

TAT-CIRP	Toll-like Receptor (TLR)	Neurological Disease
TAT-CIRP is a a small peptide, refers to Trans-trans-activating (Tat)-cold-inducible RNA binding protein. TAT-CIRP is an inhibitor of myeloid differentiation protein 2 (MD2). TAT-CIRP exhibits robust neuroprotection against ischemic and hemorrhagic stroke in mice .

HY-107666

PHA 568487	nAChR	Neurological Disease Inflammation/Immunology
PHA 568487 a selective agonist of alpha-7 nicotinic acetylcholine receptor (α-7 nAchR) .PHA 568487 reduces neuroinflammation and oxidative stress . PHA-568487 has rapid brain penetration .

Cat. No.	Product Name	Target	Research Area